1-2 of 2
Noritaka Tanaka
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers

Douglas A. Rubinson, Noritaka Tanaka, Ferran Fece de la Cruz, Kevin S. Kapner, Michael H. Rosenthal, Bryanna L. Norden, Haley Barnes, Sara Ehnstrom, Alvin A. Morales-Giron, Lauren K. Brais, Christopher T. Lemke, Andrew J. Aguirre, Ryan B. Corcoran
Journal: Cancer Discovery
Cancer Discov (2024) 14 (5): 727–736.
https://doi.org/10.1158/2159-8290.CD-23-1138
Published: 01 May 2024
View articletitled, Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers
Open the PDF for Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers in another window
Includes: Supplementary data
Journal Articles

Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation

Noritaka Tanaka, Jessica J. Lin, Chendi Li, Meagan B. Ryan, Junbing Zhang, Lesli A. Kiedrowski, Alexa G. Michel, Mohammed U. Syed, Katerina A. Fella, Mustafa Sakhi, Islam Baiev, Dejan Juric, Justin F. Gainor, Samuel J. Klempner, Jochen K. Lennerz, Giulia Siravegna, Liron Bar-Peled, Aaron N. Hata, Rebecca S. Heist, Ryan B. Corcoran
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2021) 11 (8): 1913–1922.
https://doi.org/10.1158/2159-8290.CD-21-0365
Published: 01 August 2021
View articletitled, Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation
Open the PDF for Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation in another window
Includes: Supplementary data